Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...
Hosted on MSN2mon
‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouseThe early results have included faster drug discovery, highly optimized supply chains, and greater awareness of consumer demand. For GSK’s Ramakrishnan, who has served as CDTO since 2021 ...
GSK has pledged to 100% use of renewable across the company by 2025, and an 80% reduction in carbon emissions by 2030 en route to net zero across all its supply chain – including purchased goods ...
GSK, a British drugmaker, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.
The site will house around 3,000 people – including GSK's global leadership team, and teams supporting R&D, the supply chain, commercial operations, corporate functions, and HIV joint venture ...
Chief Financial Officer Julie Brown noted, "Core operating margin improved to 29.2%, up 130 basis points year-on-year," driven by specialty medicines and supply chain efficiencies. GSK expects ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback